KPI Therapeutics Inc., of Seattle, presented preclinical data at the Inflammatory Skin Diseases Summit at the New York Academy of Medicine, demonstrating that its KPI-150 peptide has potential therapeutic benefit in atopic dermatitis and other dermatologic inflammatory diseases when administered topically in animal models.